Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Articles|September 17, 2012
Quiz on Major Depressive Disorder
Author(s)Psychiatric Times Editors
What are the advantages of adjunctive benzodiazepine therapy in comorbid depression and anxiety? Which therapy has the strongest evidence base for treating patients with late-life depression? These and more in this quiz.
Advertisement
What are the advantages of adjunctive benzodiazepine therapy in comorbid depression and anxiety? Which therapy has the strongest evidence base for treating patients with late-life depression? These and more in this quiz.
Advertisement
Related to this article
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
5